Myriad denied injunction against Ambry in patent-antitrust case over cancer testing
A Utah federal judge has denied a request for a preliminary injunction filed by Myriad Genetics against rival Ambry Genetics, which it accuses of infringing on patents related to diagnostic testing...To view the full article, register now.
Already a subscriber? Click here to view full article